Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-phenylalaninol is a chiral amino alcohol derived from the reduction of the carboxy group of L-phenylalanine to an alcohol. It is classified as an amphetamine derivative and serves primarily as a chiral building block in pharmaceutical synthesis, enabling the production of enantiomerically pure drugs. L-phenylalaninol has been studied for its anticancer and antacid activities; in melanoma cells, it increases cytochrome c reductase and tau-glutamyl transpeptidase activity while inhibiting cell proliferation. It also inhibits intestinal absorption of phenylalanine and may decrease gastric acid secretion and ulcer formation. Beyond pharmaceuticals, it is used in biochemical research on amino acid metabolism, as well as in flavoring agents, fragrances, cosmetics for moisturizing properties, and food products for its sweet taste[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-phenylalaninol.